Price movement over the last 24 hours
Alcon AG vs Gitlab Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Gitlab Inc trades at $31.53 (market cap $5.50B). The key difference: Alcon AG is far larger — about 5.9× Gitlab Inc's market cap, and Alcon AG pays a 0.54% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| ALC | GTLB | |
|---|---|---|
Market Cap | $32.69B | $5.50B |
Sector | Health | Technology |
52-Week High | $92.22 | $51.04 |
52-Week Low | $62.02 | $19.42 |
Enterprise Value | $36.28B | $4.24B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
GitLab (GTLB) trades at $32.59, up 1.62% today, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus price target of $31.86, while recent news highlights its leadership in DevSecOps and AI-driven software development.
Outlook: GitLab's growth trajectory and strategic position in AI and DevSecOps present upside potential, but profitability concerns and high valuation ratios pose risks. Investors should weigh strong revenue expansion against ongoing losses and competitive pressures in the technology sector.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →